Areolar Atrophy of the Macula

Areolar atrophy of the macula means there is a clear, well-outlined “island” of damaged (thinned or missing) tissue in the macula, the small center part of the retina that gives sharp reading vision. In this area, the retinal pigment epithelium (RPE) and the outer retina (light-sensing cells) may be lost, and sometimes the tiny blood layer under them (choriocapillaris) also becomes weak or absent. This is why vision in the center can fade slowly and a “blank spot” can appear. Doctors often describe this kind of sharply bordered macular damage as “geographic/areolar” atrophy, and then they look for the real cause (for example, late dry age-related macular degeneration or an inherited macular dystrophy). EyeWiki+2PMC+2

“Areolar atrophy of the macula” means a clear, patch-like area (“areola”) where the macula has become thin and damaged. The macula is the small center part of the retina that helps you see sharp details (reading, faces). In many people, this description matches geographic atrophy, an advanced form of dry age-related macular degeneration (AMD) where the support cells under the retina slowly die. EyeWiki+1

In areolar/geographic atrophy, the retinal pigment epithelium (RPE) and nearby layers stop working, so the “camera film” of the eye cannot feed the light-sensing cells well. Over time, this can create a center blurry spot and trouble with fine detail, while side vision often stays better for longer. EyeWiki+1

The main goals of care are to slow the damage when possible, watch closely for wet AMD (which can happen suddenly), and help you function better with low-vision tools and habits. The newest FDA-approved medicines for geographic atrophy can slow growth of the atrophy area, but they do not “restore” normal macula tissue. FDA Access Data+2FDA Access Data+2

Other names

People may hear different names because “areolar atrophy” is a description, not one single disease. Common related terms include: geographic atrophy (GA), macular RPE atrophy, central macular atrophy, well-demarcated macular atrophy, and (when it is the inherited form) central areolar choroidal dystrophy (CACD). EyeWiki+2EyeWiki+2

Types

• Primary (inherited) areolar macular atrophy (a macular dystrophy pattern)

• Secondary (acquired) areolar macular atrophy (from aging, inflammation, drugs, myopia, vascular disease, etc.)

• Fovea-sparing (the very center is still partly working)

• Fovea-involving (the center is affected)

• Single lesion (one main atrophic island)

• Multifocal lesions (several atrophic islands)

• Symmetric (similar in both eyes)

• Asymmetric (one eye worse)

These “types” are used to describe pattern and cause, and imaging like OCT and fundus autofluorescence helps doctors label them more clearly. EyeWiki+2EyeWiki+2

Causes

1) Geographic atrophy from dry age-related macular degeneration (AMD). This is one of the most common causes in older adults. The macula slowly loses outer retina and RPE in a sharply bordered patch that expands over time. EyeWiki+2PMC+2

2) Central areolar choroidal dystrophy (CACD). This is an inherited macular disease where the central macula develops progressive atrophy, often starting in adulthood. It can be linked to genes like PRPH2 in many families. EyeWiki+2AAO Journal+2

3) Stargardt disease (ABCA4-related). This inherited disease can create macular RPE atrophy that may look like a well-defined atrophic area on imaging, with central vision loss and photophobia. EyeWiki+2American Academy of Ophthalmology+2

4) Pattern dystrophies (often PRPH2-related). These are inherited macular disorders where pigment and lipofuscin changes can later progress to geographic-like macular atrophy in some people. EyeWiki+2PubMed+2

5) Best disease / bestrophinopathies (BEST1-related). In later stages, the earlier yellow material can disappear and leave an atrophic scar-like macular area, reducing central detail vision. EyeWiki+2PMC+2

6) Cone dystrophy / cone-rod dystrophy. These inherited conditions mainly damage cone cells first, so the macula can become thin and atrophic over time, causing light sensitivity and poor color vision. Nature+2NCBI+2

7) Macular telangiectasia type 2 (MacTel 2). This is a slowly progressive macular disorder where the macula can lose important outer retinal layers and later develop atrophic changes and central vision problems. EyeWiki+2PMC+2

8) Pathologic myopia (myopic macular degeneration). Very high myopia can cause patchy chorioretinal atrophy and later macular atrophy, which may look like a pale, sharply bordered area. EyeWiki+2PMC+2

9) Old (healed) choroidal neovascularization scars. New abnormal vessels under the macula (from AMD, myopia, inflammation, etc.) can heal with scarring and leave surrounding atrophy that reduces central vision. EyeWiki+2Review of Ophthalmology+2

10) Presumed ocular histoplasmosis syndrome (POHS). This condition can leave atrophic chorioretinal scars (“histo spots”), and if the fovea is involved or CNV scars form, central vision can drop. EyeWiki+2American Academy of Ophthalmology+2

11) Toxoplasma retinochoroiditis scar (posterior pole). A healed inflammatory scar in or near the macula can resemble an atrophic island and can cause a permanent central blind spot. EyeWiki+2EyeWiki+2

12) Serpiginous choroiditis / serpiginous-like choroiditis. These inflammatory diseases can damage the RPE and choroid in spreading patches; healed areas may look like geographic/areolar atrophy. Nature+2EyeWiki+2

13) Multifocal choroiditis (MFC) or punctate inner choroidopathy (PIC). These inflammatory conditions can leave multiple punched-out scars; if scars join near the macula, an areolar atrophy pattern can appear. Nature+2EyeWiki+2

14) Central serous chorioretinopathy (chronic CSCR). Long-lasting fluid under the retina can lead to RPE damage and later atrophy, sometimes forming a clear area of macular thinning. KLE Academy+2NCBI+2

15) Hydroxychloroquine/chloroquine retinal toxicity. These drugs can damage the macula and cause a “bull’s-eye” pattern and RPE/outer retina loss that can progress even after stopping in some cases. EyeWiki+2NCBI+2

16) Thioridazine retinal toxicity. This older antipsychotic can injure the RPE and outer retina and may progress to wide areas of patchy or nummular atrophy, including the macula. Retina Today+2PubMed+2

17) Radiation retinopathy (after eye/orbit radiation). Radiation can injure retinal blood vessels and the macula, leading to ischemia and later macular tissue loss and atrophy. NCBI+2EyeWiki+2

18) Retinal vascular occlusion affecting the macula. Severe lack of blood flow (artery or vein problems) can damage macular cells; later the tissue can become thin and atrophic with lasting central scotoma. NCBI+2EyeWiki+2

19) Severe macular trauma (including laser/phototoxic injury). Strong light or injury can damage the RPE/photoreceptors and leave a permanent atrophic spot in the macula that affects detail vision. EyeWiki+2American Academy of Ophthalmology+2

20) Rare crystalline or metabolic retinal disorders. Some rare conditions can cause deposits and later RPE damage and macular depigmentation/atrophy as the disease advances. EyeWiki+2NCBI+2

Symptoms

1) Blurry central vision. The macula controls sharp focus, so when macular cells are lost, the center of vision becomes less clear, especially for faces and small text. EyeWiki+2EyeWiki+2

2) Trouble reading. Letters may look faded or broken because the damaged macula cannot give crisp detail, even if side vision is still okay. NCBI+2EyeWiki+2

3) A central blind spot (central scotoma). People may notice a missing patch in the center, like a “hole” that covers what they look directly at, while side vision remains. EyeWiki+2EyeWiki+2

4) Distorted lines (metamorphopsia). Straight lines can look bent or wavy, especially if the macula is uneven or there is active disease nearby; this can be checked by an Amsler grid. American Academy of Ophthalmology+2NCBI+2

5) Reduced contrast sensitivity. People may say, “I can see it, but it looks washed out,” because macular damage reduces the ability to separate light gray from dark gray. EyeWiki+2EyeWiki+2

6) Slow adjustment from bright to dim (poor dark adaptation). Some macular disorders affect how well the retina adapts to low light, so dim places feel harder than before. EyeWiki+2EyeWiki+2

7) Light sensitivity (photophobia). In cone-related macular diseases, bright light can feel uncomfortable because cones are stressed or damaged. Nature+2EyeWiki+2

8) Color vision trouble. Colors may look less vivid or confusing because cones in the macula help color vision, and macular atrophy can reduce cone function. Nature+2PMC+2

9) Needing brighter light to read. Many people need stronger light because the macula is less efficient at fine detail tasks when it is damaged. NCBI+2EyeWiki+2

10) Difficulty recognizing faces. Faces require fine central detail, so even moderate macular loss can make face recognition difficult at normal distances. EyeWiki+2NCBI+2

11) A “gray/blank spot” that moves with the eye. Because the problem is in the retina (not the brain), the missing spot stays in the same place in vision when the eye moves. EyeWiki+2EyeWiki+2

12) Different vision between the two eyes. Many causes are bilateral, but they may not progress equally, so one eye can feel “worse” for reading. EyeWiki+2PMC+2

13) Trouble driving (especially reading signs). Signs need sharp central vision; macular atrophy can make them hard to read at distance even if you can still navigate. NCBI+2NCBI+2

14) Fixation changes (using a new “preferred retinal spot”). If the fovea is damaged, the brain may start using a nearby healthier area to look at objects, which can feel strange at first. PMC+2EyeWiki+2

15) Symptoms may be mild early on. Some people do not notice much at first, especially if the other eye compensates, so imaging can detect changes before daily life feels different. OHSU+2American Academy of Ophthalmology+2

Diagnostic tests

Physical exam (doctor’s exam in clinic)

1) Best-corrected visual acuity test (eye chart). This checks how sharp the central vision is with the best glasses or refraction. Macular atrophy often lowers this score as the fovea becomes involved. NCBI+2EyeWiki+2

2) Dilated retinal exam (fundus exam). The doctor uses drops to widen the pupil and looks for a pale, well-outlined atrophic patch in the macula and for clues to the cause (drusen, scars, pigment changes). EyeWiki+2EyeWiki+2

3) Amsler grid check (in clinic or at home). This simple grid helps detect distortion or missing spots in central vision. It does not replace imaging, but it can warn about changes. American Academy of Ophthalmology+2NCBI+2

4) Color vision testing. Simple color tests (plates or cone-based tests) can show reduced color discrimination, which is common in cone-dominant macular disorders and some dystrophies. Nature+2PMC+2

5) Contrast sensitivity testing. This measures how well you see faint patterns. Macular disease can reduce contrast even when the letter chart is not extremely low yet. EyeWiki+2EyeWiki+2

Manual / functional tests (simple “doing” tests, often office-based)

6) Central visual field test (10-2 or similar). This maps the center of vision to detect and measure a central scotoma. It is especially useful when symptoms feel bigger than what the chart shows. EyeWiki+2NCBI+2

7) Microperimetry (macular perimetry). This is a special field test that tracks the retina while testing sensitivity, so the doctor can match “weak spots” to the atrophy location and see fixation changes. EyeWiki+2Nature+2

8) Low-vision functional assessment (reading speed / preferred retinal locus training). When central scotoma exists, clinicians may test reading function and how the eye uses a healthier spot for fixation to plan rehab. American Academy of Ophthalmology+2PMC+2

Lab and pathological tests (blood tests, genetics, special labs—used when the doctor suspects a cause)

9) Genetic testing panels for inherited retinal disease. If family history or age of onset suggests a dystrophy (like CACD, Stargardt, Best), genetic testing can help confirm the diagnosis and guide counseling. EyeWiki+2EyeWiki+2

10) Infection/inflammation blood work (example: syphilis tests). If the retina looks like it had inflammation, doctors may order targeted blood tests (for example syphilis) because some infections can scar the macula. NCBI+2Nature+2

11) Toxoplasma testing (when scarring suggests it). If a pattern fits toxoplasma retinochoroiditis, doctors may use blood tests as supportive evidence along with exam and imaging. NCBI+2Nature+2

12) General inflammatory work-up (only if clinically suggested). In suspected choroiditis, doctors may check markers (like TB/sarcoid-related tests) because inflammation can damage the RPE/choroid and leave atrophy. Nature+2NCBI+2

Electrodiagnostic tests (electrical function tests of retina layers)

13) Full-field electroretinogram (ERG). ERG measures overall retinal electrical response to light. It helps tell whether the problem is mostly macular or if the wider retina is also affected. EyeWiki+2NCBI+2

14) Multifocal ERG (mfERG). mfERG checks many small areas (including the macula) at once. It can detect macular dysfunction and help separate macular disease from optic nerve problems. NCBI+2Paradigm+2

15) Electrooculogram (EOG). EOG mainly reflects RPE function and is classically used in Best disease and some other inherited macular disorders, often alongside ERG. EyeWiki+2PubMed+2

16) Visual evoked potential (VEP) when diagnosis is unclear. VEP measures signals reaching the brain and can help when doctors need to separate retinal (macular) disease from optic nerve pathway problems. Cleveland Clinic+2EyeWiki+2

Imaging tests (pictures/scans of the retina and choroid)

17) Optical coherence tomography (OCT). OCT is a non-contact scan that shows the retina in layers. In areolar macular atrophy, OCT can show thinning and loss of outer retinal bands and RPE damage. American Academy of Ophthalmology+2EyeWiki+2

18) Fundus autofluorescence (FAF). FAF maps natural signals from lipofuscin in the RPE. Areas of atrophy often appear dark (low autofluorescence), and FAF helps measure lesion size and growth. EyeWiki+2IOVS+2

19) Color fundus photography. Standard retinal photos document the shape and border of the atrophic area over time and help compare changes between visits. EyeWiki+2American Macular Degeneration Foundation+2

20) Fluorescein angiography (FA) and/or OCT-angiography (OCTA) when needed. FA uses dye photos to study retinal circulation, and OCTA is a dye-free vessel map. Doctors use these to check for hidden abnormal vessels (CNV) that can worsen central vision. American Academy of Ophthalmology+2American Academy of Ophthalmology+2

Non-pharmacological treatments (therapies and others)

1. Stop smoking (or avoid second-hand smoke).
   Purpose: reduce a strong risk factor for AMD worsening. Mechanism: smoking increases oxidative stress and harms blood flow to retina tissues. Description: quitting helps your whole body and may slow eye damage over time. National Eye Institute+1

2. Healthy “eye-support” eating pattern.
   Purpose: support retina health. Mechanism: antioxidants and healthy fats reduce oxidative stress and inflammation. Description: focus on vegetables (especially leafy greens), fruits, fish, nuts, beans, whole grains. National Eye Institute

3. Regular physical activity (most days).
   Purpose: support circulation and general health. Mechanism: better heart and vessel health can support eye blood supply and reduce risk factors linked with AMD. Description: walking, cycling, or any safe activity you can keep doing. National Eye Institute

4. Control blood pressure.
   Purpose: protect small vessels that feed the retina. Mechanism: less vessel stress and less long-term damage to blood supply. Description: follow clinician advice for diet, sleep, exercise, and medicines if prescribed. National Eye Institute

5. Control diabetes (if present).
   Purpose: reduce extra retina injury from high sugar. Mechanism: stable blood sugar reduces vessel leakage and inflammation that can worsen vision problems. Description: follow diabetes plan and eye exam schedule carefully. National Eye Institute+1

6. Protect eyes from strong sunlight (UV/blue light exposure).
   Purpose: reduce light-related stress. Mechanism: sunglasses and hats lower high-energy light reaching the retina. Description: use UV-blocking sunglasses and a brimmed hat outdoors. National Eye Institute

7. Use an Amsler grid (home monitoring).
   Purpose: catch sudden new distortion early (possible wet AMD). Mechanism: the grid helps you notice new wavy lines or missing spots quickly. Description: test each eye separately; report sudden changes urgently. American Academy of Ophthalmology+1

8. Regular retina checkups (eye doctor tracking).
   Purpose: monitor progression and detect wet conversion. Mechanism: exams and scans (like OCT) find changes before you feel them. Description: keep follow-ups even if symptoms feel stable. National Eye Institute+1

9. Low-vision rehabilitation program.
   Purpose: improve daily function and independence. Mechanism: training + tools help your brain use remaining vision better. Description: includes reading strategies, device training, and home tips. NCBI+1

10. Task lighting upgrade (bright, directed light).
    Purpose: make details easier to see. Mechanism: more light improves contrast and reduces blur impact. Description: use adjustable lamps aimed at the page/work, not into your eyes. NCBI

11. High-contrast changes at home/school.
    Purpose: reduce mistakes and falls. Mechanism: contrast makes edges clearer for reduced central vision. Description: bold labels, dark placemats for light plates, contrast tape on steps. NCBI

12. Optical magnifiers (handheld/stand magnifiers).
    Purpose: reading and near tasks. Mechanism: makes the image larger so healthier retina areas can see it. Description: choose magnifier strength with a low-vision specialist. NCBI+1

13. Electronic magnifiers and phone accessibility.
    Purpose: flexible reading and learning. Mechanism: zoom + contrast + text-to-speech reduce dependence on central detail vision. Description: use screen magnifier, bold fonts, voice tools. NCBI

14. Large-print and audio learning tools.
    Purpose: keep studying/working with less strain. Mechanism: replaces fine visual detail with bigger text or sound. Description: large-print books, audiobooks, speech-to-text. NCBI

15. Eccentric viewing training (“look slightly away”).
    Purpose: use side retina to read better. Mechanism: trains fixation so you use a healthier retinal spot near the atrophy. Description: taught in low-vision rehab; improves speed and comfort. NCBI+1

16. Driving safety evaluation (if you drive).
    Purpose: prevent accidents. Mechanism: formal testing checks if vision meets legal and safety needs. Description: many people need to stop or change driving habits as macula worsens. NCBI

17. Mental health support and stress care.
    Purpose: reduce anxiety/depression linked with vision loss. Mechanism: counseling and coping skills improve confidence and daily function. Description: support groups can help you learn practical tricks, too. NCBI+1

18. Fall-prevention plan.
    Purpose: reduce injury risk. Mechanism: clear pathways and better lighting compensate for reduced detail vision. Description: remove clutter, add railings, use non-slip mats. NCBI

19. Treat dry eye if present (comfort + clearer vision).
    Purpose: reduce blur from poor tear film. Mechanism: stable tears improve image quality reaching the retina. Description: warm compresses, blinking breaks, doctor-guided drops. FDA Access Data

20. Plan school/work accommodations early.
    Purpose: keep performance strong. Mechanism: accommodations reduce reliance on tiny visual details. Description: seating near board, digital notes, extra time, larger fonts. NCBI

---

Drug treatments

1. SYFOVRE (pegcetacoplan) – for geographic atrophy secondary to AMD.
   Class: complement inhibitor (C3). Dosage/Time: intravitreal injection monthly or every other month (by retina specialist). Purpose/Mechanism: slows growth of GA lesions by reducing complement over-activity. Side effects: eye inflammation, infection risk, retinal detachment; rare severe retinal vasculitis has been reported in warnings. FDA Access Data+1

2. IZERVAY (avacincaptad pegol) – for geographic atrophy secondary to AMD.
   Class: complement inhibitor (C5). Dosage/Time: intravitreal injection every ~28 days. Purpose/Mechanism: slows GA lesion growth by blocking complement C5 activity. Side effects: injection-related infection/inflammation risks; may increase chance of wet AMD in some patients, so monitoring matters. FDA Access Data+2FDA Access Data+2

3. EYLEA (aflibercept) – for wet AMD (if it develops).
   Class: anti-VEGF. Dosage/Time: intravitreal injection; often monthly at first, then spaced by doctor plan. Purpose/Mechanism: blocks VEGF to reduce abnormal vessel growth and leakage. Side effects: endophthalmitis risk, eye pain, pressure rise; rare stroke/heart risks are monitored. FDA Access Data

4. EYLEA HD (aflibercept 8 mg) – higher-dose anti-VEGF option for retina diseases.
   Class: anti-VEGF. Dosage/Time: intravitreal injection; schedules can extend in some patients (doctor decides). Purpose/Mechanism: stronger/longer VEGF blockade for abnormal vessels and fluid. Side effects: similar injection risks: infection, inflammation, pressure rise. FDA Access Data+1

5. LUCENTIS (ranibizumab) – for wet AMD (if it develops).
   Class: anti-VEGF antibody fragment. Dosage/Time: intravitreal injection, commonly monthly then tailored. Purpose/Mechanism: reduces leakage and bleeding from abnormal macular vessels. Side effects: injection infection risk, eye inflammation, pressure rise. FDA Access Data+1

6. VABYSMO (faricimab) – for wet AMD and other retina fluid diseases.
   Class: anti-VEGF/anti-Ang-2 (dual pathway). Dosage/Time: intravitreal injection with treat-and-extend schedules in many patients. Purpose/Mechanism: reduces abnormal vessels and leakage by blocking VEGF and Ang-2 pathways. Side effects: injection risks; inflammation and pressure rise possible. FDA Access Data+1

7. BEOVU (brolucizumab) – for wet AMD (selected patients).
   Class: anti-VEGF. Dosage/Time: intravitreal injection (doctor-scheduled). Purpose/Mechanism: reduces leakage and swelling from abnormal vessels. Side effects: important warning history for intraocular inflammation/retinal vasculitis in some patients; careful monitoring is needed. FDA Access Data

8. SUSVIMO (ranibizumab port delivery system) – long-acting delivery for wet AMD.
   Class: implanted refillable delivery system with ranibizumab. Dosage/Time: surgical implant + periodic refills by specialist. Purpose/Mechanism: maintains anti-VEGF levels longer to reduce injection frequency. Side effects: implant complications + infection risk; strict follow-up is required. FDA Access Data+1

9. BYOOVIZ (ranibizumab-nuna) – ranibizumab biosimilar for wet AMD.
   Class: anti-VEGF biosimilar. Dosage/Time: intravitreal injection schedule similar to ranibizumab. Purpose/Mechanism: same VEGF blocking goal to control wet AMD changes. Side effects: injection-related risks similar to ranibizumab products. FDA Access Data+1

10. CIMERLI (ranibizumab-eqrn) – interchangeable ranibizumab biosimilar.
    Class: anti-VEGF biosimilar. Dosage/Time: intravitreal injection (doctor-scheduled). Purpose/Mechanism: blocks VEGF to treat abnormal macular vessels. Side effects: infection/inflammation/pressure risks similar to anti-VEGF injections. FDA Access Data+1

11. MACUGEN (pegaptanib) – older wet AMD treatment (used less now).
    Class: anti-VEGF aptamer (targets VEGF165). Dosage/Time: intravitreal injection (specialist). Purpose/Mechanism: reduces VEGF activity to slow vessel leakage. Side effects: injection-related infection/inflammation risks. FDA Access Data

12. AVASTIN (bevacizumab) – often used off-label in the eye for wet AMD.
    Class: anti-VEGF monoclonal antibody. Dosage/Time: intravitreal injection is off-label (drug is FDA-approved for cancers). Purpose/Mechanism: blocks VEGF to reduce abnormal vessel growth/leakage. Side effects: injection risks; systemic VEGF-block risks are monitored. FDA Access Data

13. VISUDYNE (verteporfin) – photodynamic therapy drug for certain wet AMD cases.
    Class: photosensitizer used with laser (PDT). Dosage/Time: IV infusion + timed laser procedure (clinic). Purpose/Mechanism: light activates the drug to close abnormal vessels while sparing much normal tissue. Side effects: light sensitivity for a period, infusion reactions, vision changes. FDA Access Data+2PubMed+2

14. OZURDEX (dexamethasone intravitreal implant) – for macular edema/uveitis (not GA itself).
    Class: corticosteroid implant. Dosage/Time: intravitreal implant (specialist). Purpose/Mechanism: reduces inflammation and swelling when macular edema coexists from other causes. Side effects: cataract, eye pressure rise, infection risk. FDA Access Data

15. YUTIQ (fluocinolone acetonide intravitreal implant) – for chronic non-infectious uveitis.
    Class: long-acting corticosteroid implant. Dosage/Time: intravitreal implant lasting years (specialist). Purpose/Mechanism: controls inflammation that can damage retina/macula in uveitis (a different cause than AMD). Side effects: cataract and glaucoma/pressure rise. FDA Access Data+1

16. ILUVIEN (fluocinolone acetonide implant) – for diabetic macular edema (not GA itself).
    Class: corticosteroid implant. Dosage/Time: intravitreal implant (specialist). Purpose/Mechanism: reduces inflammatory pathways driving macular swelling in diabetes. Side effects: cataract, eye pressure rise, infection risk. FDA Access Data

17. KENALOG-40 (triamcinolone acetonide) – steroid injection (sometimes used off-label in eye).
    Class: corticosteroid. Dosage/Time: route/dose depends on condition; eye use is specialist-only and often off-label. Purpose/Mechanism: calms strong inflammation and reduces swelling in select macular diseases. Side effects: steroid risks (pressure rise, infection risk, blood sugar rise). FDA Access Data+1

18. RESTASIS (cyclosporine ophthalmic) – for dry eye that worsens blur.
    Class: topical immunomodulator. Dosage/Time: 1 drop twice daily. Purpose/Mechanism: reduces surface inflammation and increases tear production, improving comfort and clarity (does not treat GA). Side effects: burning/stinging, redness. FDA Access Data

19. HUMIRA (adalimumab) – for non-infectious uveitis (different cause of macular damage).
    Class: TNF-alpha inhibitor biologic. Dosage/Time: injection schedule per label and specialist. Purpose/Mechanism: controls immune inflammation that can injure retina/macula in uveitis (not AMD). Side effects: serious infection risk, injection reactions; careful screening is required. FDA Access Data

20. Systemic immunosuppressants (examples: methotrexate, mycophenolate, azathioprine) – for inflammatory macular disease, not AMD.
    Class: immunosuppressants. Dosage/Time: varies by doctor and diagnosis. Purpose/Mechanism: lowers harmful immune attack in uveitis/autoimmune retinopathy that can look like “atrophy.” Side effects: infection risk, liver/blood effects; close lab monitoring is needed. FDA Access Data+2FDA Access Data+2

---

Dietary molecular supplements

1. AREDS2-style antioxidant + mineral formula (core evidence).
   Dosage (classic AREDS2 amounts): Vitamin C 500 mg, Vitamin E 400 IU, Zinc (often 80 mg as zinc oxide), Copper 2 mg, Lutein 10 mg, Zeaxanthin 2 mg (many products use a lower zinc dose). Function/Mechanism: reduces oxidative stress; shown to lower risk of progression in intermediate AMD (not a cure). National Eye Institute

2. Lutein.
   Dosage: commonly 10 mg/day (often within AREDS2). Function/Mechanism: macular pigment that filters light and acts as an antioxidant; supports retinal stress defense. Note: best evidence is in AREDS2 context rather than alone. National Eye Institute

3. Zeaxanthin.
   Dosage: commonly 2 mg/day (often within AREDS2). Function/Mechanism: supports macular pigment and antioxidant protection. Note: used as a safer substitute for beta-carotene in smokers/former smokers. National Eye Institute

4. Zinc (with copper).
   Dosage: commonly 25–80 mg/day zinc + 2 mg copper (AREDS/AREDS2 used zinc and copper together). Function/Mechanism: supports retinal enzyme systems and antioxidant defense. Caution: high zinc without copper can contribute to copper deficiency. National Eye Institute

5. Vitamin C.
   Dosage: often 500 mg/day in AREDS formulas. Function/Mechanism: antioxidant support that helps reduce oxidative stress. Caution: supplements can upset stomach in some people. National Eye Institute

6. Vitamin E.
   Dosage: often 400 IU/day in AREDS formulas. Function/Mechanism: fat-soluble antioxidant that supports cell membranes. Caution: high-dose vitamin E may not be safe for everyone (ask clinician, especially if on blood thinners). National Eye Institute

7. Omega-3 fatty acids (DHA/EPA) – food is preferred.
   Dosage: varies (often 1–2 g/day combined EPA+DHA in supplements). Function/Mechanism: supports vessel and anti-inflammatory pathways. Evidence note: AREDS2 did not show overall added benefit from omega-3 supplements, so focus on diet unless your clinician advises otherwise. National Eye Institute+1

8. Vitamin D (if deficient).
   Dosage: depends on blood level and clinician plan. Function/Mechanism: supports immune balance and general health; direct AMD benefit is not proven, but correcting deficiency is good for health. National Eye Institute

9. Saffron extract (limited evidence).
   Dosage: varies by product (often around 20 mg/day in studies). Function/Mechanism: antioxidant carotenoids may support retinal function. Evidence note: promising small studies exist, but it is not a standard guideline therapy. National Eye Institute

10. Bilberry/anthocyanins (limited evidence).
    Dosage: varies by product. Function/Mechanism: antioxidant effects may help eye fatigue and micro-circulation. Evidence note: not proven to slow geographic atrophy; consider food sources (berries) first. National Eye Institute

---

Immunity booster / regenerative / stem cell” medicines (important truth)

There are no FDA-approved “stem cell drugs” that cure areolar/geographic macular atrophy today; stem-cell and retinal-implant approaches are still developing in research settings. PubMed+1

1. Gene therapy example (regenerative medicine): LUXTURNA (voretigene neparvovec).
   Use: for confirmed biallelic RPE65 retinal dystrophy, not AMD. Mechanism: delivers a working RPE65 gene to retinal cells to improve function. Why listed: sometimes “macular atrophy” words are used in inherited diseases, so correct diagnosis matters. U.S. Food and Drug Administration+1

2. HUMIRA (adalimumab) – immune control (not a booster).
   Use: non-infectious uveitis can damage the macula. Mechanism: blocks TNF-alpha to reduce harmful inflammation. Key point: this medicine can increase infection risk; it is not for self-use and not for AMD. FDA Access Data

3. Methotrexate – immune control (not a booster).
   Use: sometimes used by specialists for inflammatory eye disease. Mechanism: reduces overactive immune activity (folate pathway effects). Caution: needs lab monitoring; can affect liver and blood counts. FDA Access Data+1

4. Mycophenolate mofetil (CellCept) – immune control.
   Use: used in some autoimmune/inflammatory conditions under specialist care. Mechanism: reduces lymphocyte growth by blocking purine synthesis. Caution: infection risk and pregnancy warnings; careful monitoring needed. FDA Access Data+1

5. Azathioprine (Imuran) – immune control.
   Use: sometimes used for autoimmune inflammation affecting eyes. Mechanism: limits DNA building blocks to reduce immune attack. Caution: cancer risk warning and blood/liver monitoring needs. FDA Access Data+1

6. Cyclosporine – immune control (systemic), and also eye-drop form for dry eye.
   Use: systemic cyclosporine is immunosuppressive; topical cyclosporine helps dry eye inflammation. Mechanism: reduces T-cell activation. Caution: systemic form has significant side effects; topical form is safer but still can sting. FDA Access Data+1

---

Surgeries / procedures (and why they are done)

1. Implantable Miniature Telescope (IMT) surgery (for end-stage AMD vision loss).
   Why: improves ability to see details by magnifying images onto healthier retina areas in selected patients. Procedure: implanted in one eye as part of a special program; it is an FDA-approved device for end-stage AMD. FDA Access Data+1

2. Cataract surgery (if cataract is also present).
   Why: cataract can add extra blur on top of macular atrophy; removing it may improve overall clarity (but does not fix the macula). Procedure: standard lens removal + IOL; doctor decides benefit vs risk. CRS Today+1

3. Photodynamic therapy (PDT) with verteporfin (for certain wet AMD patterns).
   Why: closes abnormal leaking vessels when wet AMD is present or in special cases. Procedure: verteporfin infusion + laser activation at the retina clinic. PubMed+1

4. Thermal laser photocoagulation (rare, selected wet AMD cases).
   Why: can seal some abnormal vessels, but it can also damage retina, so it is used far less today than anti-VEGF injections. Procedure: office laser treatment guided by retina imaging. National Eye Institute

5. Subretinal photovoltaic implant surgery (research/clinical trials for geographic atrophy).
   Why: aims to restore some central vision using an implant + special glasses; not routine care yet. Evidence: an NEJM study in geographic atrophy reported improved visual function in a trial setting. PubMed+1

---

Preventions

1. Don’t smoke. National Eye Institute+1

2. Eat leafy greens and colorful vegetables often. National Eye Institute

3. Eat fish (omega-3 in food) regularly if you can. National Eye Institute+1

4. Keep a healthy weight and stay active. National Eye Institute

5. Control blood pressure and cholesterol with clinician guidance. National Eye Institute+1

6. Protect eyes from strong sun (UV-blocking sunglasses, hat). National Eye Institute

7. Manage diabetes carefully if you have it. National Eye Institute

8. Do home monitoring (Amsler grid) and report sudden changes fast. American Academy of Ophthalmology+1

9. Keep regular eye checkups even when you feel “okay.” National Eye Institute

10. Ask your eye doctor if AREDS2 is right for your stage (not for everyone). National Eye Institute+1

---

When to see a doctor urgently

Go to an eye doctor as soon as possible (same day or within 24–48 hours) if you suddenly notice new wavy lines, a new dark/blank spot, fast vision drop, new bleeding-like blur, or straight lines becoming bent, because this can signal wet AMD, which needs quick treatment. American Academy of Ophthalmology+1

Also seek urgent care after any eye injection or eye procedure if you develop severe eye pain, strong redness, light sensitivity, or a big drop in vision, because these can be signs of serious infection or inflammation. FDA Access Data+2FDA Access Data+2

---

 What to eat and what to avoid

1. Eat: spinach/kale and other leafy greens (lutein/zeaxanthin). Avoid: skipping vegetables most days. National Eye Institute+1

2. Eat: fatty fish (like salmon/sardines) when possible. Avoid: very low-fish diets if you can safely include fish. National Eye Institute

3. Eat: eggs (a source of lutein/zeaxanthin). Avoid: ultra-processed snack patterns. National Eye Institute+1

4. Eat: nuts and seeds (healthy fats). Avoid: trans fats and deep-fried foods often. National Eye Institute

5. Eat: beans/legumes (steady energy). Avoid: very high sugar drinks daily. National Eye Institute

6. Eat: colorful fruits (berries, oranges). Avoid: relying only on refined carbs. National Eye Institute

7. Eat: whole grains. Avoid: white bread/refined flour as the main staple all day. National Eye Institute

8. Eat: olive oil or other unsaturated oils. Avoid: repeated reheated oils and heavy saturated-fat meals. National Eye Institute

9. Eat: enough water + balanced meals. Avoid: smoking and second-hand smoke exposure. Macular Society+1

10. Eat: AREDS2 only if your eye doctor says your AMD stage benefits. Avoid: high-dose supplements without medical advice (can interact with medicines). National Eye Institute+1

---

FAQs

1. Is areolar macular atrophy the same as “dry AMD”?
   Often it describes advanced dry AMD (geographic atrophy), but similar “atrophy” words can also be used in inherited or inflammatory diseases—so diagnosis matters. EyeWiki+1

2. Can it be cured?
   There is no cure that restores the macula back to normal, but some treatments can slow progression and help you function better. National Eye Institute+1

3. Do SYFOVRE or IZERVAY bring vision back?
   They are designed to slow the growth of geographic atrophy lesions; they do not rebuild lost retina tissue. FDA Access Data+1

4. Why do I see a missing spot in the center?
   The macula is the center “detail” zone; when support cells die there, the center image becomes blurred or missing. EyeWiki+1

5. Can dry AMD turn into wet AMD?
   Yes. Some people develop wet AMD changes, which can cause fast distortion and needs urgent treatment. National Eye Institute+1

6. What is the quickest warning sign of wet AMD?
   New wavy lines or sudden distortion on an Amsler grid (or in real life) is a classic warning sign. American Academy of Ophthalmology+1

7. Are anti-VEGF injections used for areolar atrophy itself?
   Anti-VEGF medicines are mainly for wet AMD, not for pure geographic atrophy—unless wet changes appear. FDA Access Data+1

8. Do vitamins help everyone?
   No. AREDS2-type supplements help specific AMD stages (especially intermediate AMD) and are not meant for everyone. National Eye Institute+1

9. Is beta-carotene safe in eye vitamins?
   In AREDS2, beta-carotene raised lung-cancer risk in former smokers, so lutein/zeaxanthin is preferred in that group. National Eye Institute

10. Will reading damage my eyes more?
    Reading does not “wear out” the macula, but it can feel harder; tools like magnifiers and better lighting make it easier. NCBI+1

11. What helps most with daily life?
    Low-vision rehabilitation and the right devices (optical or digital) have strong evidence for improving function and quality of life. NCBI+1

12. Is surgery available for end-stage AMD?
    A special telescope implant (IMT) is FDA-approved for some end-stage AMD patients, and other implants are being studied. FDA Access Data+1

13. Are “stem cell cures” available now?
    Not as an FDA-approved cure for geographic atrophy. Most stem-cell approaches remain research/clinical-trial work. PubMed+1

14. How often should I see an eye doctor?
    It depends on severity and treatments; your doctor will set a schedule, and you should go sooner if you notice sudden changes. National Eye Institute+1

15. What single habit matters most?
    If you smoke, stopping is one of the strongest risk-reduction steps, and it also improves overall health. Macular Society+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: December 16, 2025.